A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis

Leukemia Research

Volumn 39, Issue 2, 2015, Pages 157-163

  Verstovsek, Srdan ^a   Hoffman, Ronald ^b   Mascarenhas, John ^b   Soria, Jean Charles ^c   Bahleda, Ratislav ^c   McCoon, Patricia ^d   Tang, Weifeng ^d   Cortes, Jorge ^a   Kantarjian, Hagop ^a   Ribrag, Vincent ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d ASTRAZENECA   (United Kingdom)

Author keywords

AZD1480; JAK2 mutation; Myelofibrosis

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; AMNESIA; ANEMIA; APHASIA; ARTICLE; ASTHENIA; ATAXIA; BASAL CELL CARCINOMA; BONE PAIN; CATARACT; CLINICAL ARTICLE; CONFUSION; CONJUNCTIVAL HEMORRHAGE; CORONARY ARTERY DISEASE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSARTHRIA; DYSPNEA; EYE DISEASE; FATIGUE; FEMALE; FEVER; HEADACHE; HEMORRHOID; HUMAN; KERATITIS; LOBAR PNEUMONIA; LUNG INFILTRATE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MYELOFIBROSIS; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PARESTHESIA; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRESYNCOPE; PROTEINURIA; RETINA HEMORRHAGE; RISK ASSESSMENT; SPLEEN INFARCTION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; WEIGHT GAIN; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; ENZYMOLOGY; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS;

AGED; AGED, 80 AND OVER; ANEMIA; DIZZINESS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PYRAZOLES; PYRIMIDINES;

EID: 84921434895     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.11.018     Document Type: Article

References (24)

1. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005, 23:8520-8530.
2. Mesa R.A. The evolving treatment paradigm in myelofibrosis. Leuk Lymphoma 2013, 54:242-251.
3. Mesa R.A., Niblack J., Wadleigh M., Verstovsek S., Camoriano J., Barnes S., et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007, 109:68-76.
4. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
5. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
6. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
7. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
8. Oh S.T., Gotlib J. JAK2, V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Exp Rev Hematol 2010, 3:323-337.
9. Quintas-Cardama A., Verstovsek S. Molecular pathways: JAK/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res 2013, 19:1933-1940.
10. Tam C.S., Verstovsek S. Investigational Janus kinase inhibitors. Expert Opin Investig Drugs 2013, 22:1-13.
11. Hedvat M., Huszar D., Herrmann A., Gozgit J.M., Schroeder A., Sheehy A., et al. The JAK2 inhibitor, AZD1480, potently blocks STAT3 signaling and oncogenesis in solid tumors. Cancer Cell 2009, 16:487-497.
12. Mesa R.A., Verstovsek S., Cervantes F., Barosi G., Reilly J.T., Dupriez B., et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007, 31:737-740.
13. Dupriez B., Morel P., Demory J.L., Lai J.L., Simon M., Plantier I., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996, 88:1013-1018.
14. Tefferi A., Barosi G., Mesa R.A., Cervantes F., Deeg H.J., Reilly J.T., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006, 108:1497-1503.
15. Campbell I.L. Cytokine-mediated inflammation, tumorigenesis, and disease-associated JAK/STAT/SOCS signaling circuits in the CNS. Brain Res Brain Res Rev 2005, 48:166-177.
16. Nicolas C.S., Peineau S., Amici M., Csaba Z., Fafouri A., Javalet C., et al. The Jak/STAT pathway is involved in synaptic plasticity. Neuron 2012, 73:374-390.
17. Huang E.J., Reichardt L.F. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003, 72:609-642.
18. Thress K., Macintyre T., Wang H., Whitston D., Liu Z.Y., Hoffmann E., et al. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther 2009, 8:1818-1827.
19. Pardanani A., Laborde R.R., Lasho T.L., Finke C., Begna K., Al-Kali A., et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013, 27:1322-1327.
20. Verstovsek S., Tam C.S., Wadleigh M., Sokol L., Smith C.C., Bui L.A., et al. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res 2014, 38:316-322.
21. Wicklund M.R., Knopman D.S. Brain MRI findings in Wenicke encephalopathy. Neurol Clin Pract 2013, 3:363-364.
22. Pardanani A., Gotlib J., Gupta V., Roberts A.W., Wadleigh M., Sirhan S., et al. Update on the long-term safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Blood 2013, 122:108.
23. Zhang Q., Zhang Y., Diamond S., Boer J., Harris J.J., Li Y., et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy. Drug Metab Dispos 2014, 42:1656-1662.
24. Pilmack E.R., LoRusso P.M., McCoon P., Tang W., Krebs A.D., Curt G., et al. AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist 2013, 18:819-820.